DaVita (NYSE:DVA) Issues FY24 Earnings Guidance

DaVita (NYSE:DVA) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $9.00-$9.80 for the period, compared to the consensus EPS estimate of $9.30.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DVA. StockNews.com raised DaVita from a buy rating to a strong-buy rating in a research note on Thursday, April 25th. Barclays started coverage on DaVita in a research note on Wednesday, March 6th. They set an equal weight rating and a $133.00 price objective on the stock. TheStreet upgraded shares of DaVita from a c+ rating to a b- rating in a report on Wednesday, February 7th. UBS Group increased their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a buy rating in a report on Wednesday, February 14th. Finally, Truist Financial increased their target price on shares of DaVita from $130.00 to $135.00 and gave the stock a hold rating in a report on Tuesday, February 20th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $118.50.

DaVita Stock Up 1.8 %

DVA traded up $2.49 on Thursday, hitting $142.24. The company had a trading volume of 1,859,057 shares, compared to its average volume of 818,934. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita has a 52-week low of $71.51 and a 52-week high of $143.23. The stock has a fifty day simple moving average of $133.13 and a 200-day simple moving average of $111.96. The firm has a market capitalization of $12.47 billion, a P/E ratio of 18.89, a P/E/G ratio of 1.24 and a beta of 1.04.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same quarter in the previous year, the firm posted $1.58 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, equities analysts expect that DaVita will post 9.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares in the company, valued at approximately $2,424,384.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Michael David Staffieri sold 29,488 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the transaction, the chief operating officer now directly owns 37,687 shares in the company, valued at $4,515,279.47. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock worth $16,551,071 in the last 90 days. 1.40% of the stock is currently owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.